<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03263117</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-17-0436</org_study_id>
    <nct_id>NCT03263117</nct_id>
  </id_info>
  <brief_title>SEdation Versus General Anesthesia for Endovascular Therapy in Acute Ischemic Stroke</brief_title>
  <acronym>SEGA</acronym>
  <official_title>SEGA - SEdation Versus General Anesthesia for Endovascular Therapy in Acute Ischemic Stroke - a Randomized Comparative Effectiveness Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stryker Neurovascular</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives:&#xD;
&#xD;
      This study aims to estimate overall treatment benefit (improvement in disability) among acute&#xD;
      ischemic stroke patients that are randomized to General Anesthesia (GA) compared with&#xD;
      Sedation (CS) during endovascular therapy. Assess safety (as measured by incidence of&#xD;
      symptomatic intracranial hemorrhage); rates of Endovascular therapy (EVT) procedural&#xD;
      complications, reperfusion; and quality of life.&#xD;
&#xD;
      Hypothesis:&#xD;
&#xD;
      GA during EVT for acute ischemic stroke improves functional outcomes at 90 days compared to&#xD;
      sedation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Anticipated">February 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>modified Rankin Scale (mRS)</measure>
    <time_frame>90 days</time_frame>
    <description>Comparison of independent clinical outcome as measured by the modified Rankin Scale (mRS) at 90 days (scores 5 and 6 combined) among patients randomized to GA versus Sedation assessed by study personnel blinded to treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dichotomized modified Rankin Scale (mRS)</measure>
    <time_frame>90 days</time_frame>
    <description>Dichotomized modified Rankin Scale (mRS) at 90 days (0-2 vs 3-6) adjusted for stratification variable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of recanalization</measure>
    <time_frame>post procedure within 6 hours</time_frame>
    <description>Rates of recanalization using modified TICI scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Institute of Health Stroke Scale (NIHSS) scale</measure>
    <time_frame>24-36 hours post procedure</time_frame>
    <description>Early clinical improvement measured by difference NIHSS scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>modified Rankin Scale (mRS)</measure>
    <time_frame>90 days</time_frame>
    <description>Independent functional outcome in General Anesthesia patients treated with inhalational vs. intravenous medications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as assessed by the European Quality of Life-5 Dimensions (EQ-5D) instrument</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of symptomatic intracerebral hemorrhage</measure>
    <time_frame>18-36 hours post procedure</time_frame>
    <description>Safety measured by incidence of symptomatic intracerebral hemorrhage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of mortality</measure>
    <time_frame>18-36 hours post procedure</time_frame>
    <description>Safety measured by incidence of mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of device related complications</measure>
    <time_frame>18-36 hours post procedure</time_frame>
    <description>Safety measured by incidence of device related complications</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Sedation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The protocol does not specify a particular combination of drugs that must be used for sedation. The choice of specific drugs and dosages for achieving sedation will be up to the anesthesiologist.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>General Anesthesia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The protocol does not specify a particular combination of drugs that must be used for general anesthesia. The choice of specific drugs and dosages for achieving general anesthesia will be up to the anesthesiologist.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sedation</intervention_name>
    <description>The protocol does not specify a particular combination of drugs that must be used for sedation.&#xD;
The most common drugs utilized for sedation and wide dosing ranges are included in the protocol (i.e., sedation will be provided under the supervision of an anesthesiologist and may use a combination of fentanyl, midazolam, dexmedetomidine infusion (with or without loading dose), and/or low-dose propofol by intermittent bolus or infusion); however, the choice of specific drugs and dosages for achieving conscious sedation or general anesthesia will not be specified by the protocol but will be up to the anesthesiologist.</description>
    <arm_group_label>Sedation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>General Anesthesia (GA)</intervention_name>
    <description>The protocol doesn't specify drugs that must be used for GA, the choice of drugs and dosages for achieving general anesthesia will not be specified by the protocol but will be up to the anesthesiologist.&#xD;
The most common drugs utilized for GA and wide dosing ranges included in the protocol are (GA will be provided under the supervision of an anesthesiologist and induction of anesthesia may be achieved with propofol and/or etomidate; muscle paralysis may be achieved with succinylcholine or non-depolarizing paralytic (rocuronium or vecuronium); and adjuvant lidocaine and fentanyl; if intravenous maintenance of anesthesia is used, it may be achieved by propofol infusion at 50 to 150 mcg/kg/min with redosing of non-depolarizing paralytic and fentanyl as needed; if inhalational maintenance of anesthesia is used it will be achieved with sevoflurane 1% to 2% or desflurane 3% to 6% end-tidal concentration with redosing of non-depolarizing paralytic and fentanyl as needed)</description>
    <arm_group_label>General Anesthesia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intra-arterial Thrombectomy</intervention_name>
    <description>The first line therapeutic embolectomy device should be a stent retriever. Additional Endovascular therapies including, but not limited to, intra- or extracranial angioplasty Â± stenting; antithrombotics (oral, IV or IA antiplatelets or anticoagulants) intra-arterial thrombolytics; are left to the decision of the local treatment team.</description>
    <arm_group_label>General Anesthesia</arm_group_label>
    <arm_group_label>Sedation</arm_group_label>
    <other_name>Endovascular Therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Acute ischemic stroke due to large intracranial vessel occlusion demonstrated on&#xD;
             CT-angiography in the following anterior circulation locations that will be treated by&#xD;
             endovascular therapy (EVT):&#xD;
&#xD;
               1. Internal Carotid Artery (terminal &quot;T&quot; or &quot;L-type&quot;- occlusion)&#xD;
&#xD;
               2. Middle Cerebral Artery (MCA) M1 or proximal M2&#xD;
&#xD;
               3. Anterior Cerebral Artery (ACA) A1 or proximal A2&#xD;
&#xD;
                    -  Patients who receive IV-tPA thrombolysis are eligible provided the drug was&#xD;
                       delivered within 4.5 hours of stroke onset or last seen normal and in&#xD;
                       accordance with local hospital standard of care.&#xD;
&#xD;
          2. Ages 18-90.&#xD;
&#xD;
          3. National Institute of Health Stroke Scale (NIHSS) score 6-30&#xD;
&#xD;
          4. Time of from stroke symptom onset of last seen normal to start of EVT (defined as&#xD;
             groin puncture) â¤ 16 hours.&#xD;
&#xD;
          5. Limited infarct core, as defined below and adapted from the 2018 American Heart&#xD;
             Association guidelines&#xD;
&#xD;
               1. For patients presenting â¤ 6 hours from time of symptom onset or last seen normal,&#xD;
                  Alberta Stroke Program Early Computed Tomography Score (ASPECTS) â¥ 6&#xD;
&#xD;
               2. For patients presenting &gt; 6 hours and â¤ 16 hours from time of symptom onset or&#xD;
                  last seen normal, they must satisfy EITHER ONE of the two following criteria:&#xD;
&#xD;
             i. Ischemic core by CT Perfusion or MRI/MR Perfusion &lt; 70 mL, a ratio of volume of&#xD;
             penumbral tissue to infarct core of â¥ 1.8, and and absolute volume of penumbral tissue&#xD;
             of â¥ 15 mL OR ii. For patients with NIHSS â¥ 10, infarct core of &lt; 31 mL by CT&#xD;
             Perfusion or MRI; For patients with NIHSS â¥ 20, infarct core &lt; 51 mL.&#xD;
&#xD;
          6. Subject willing/able to return for protocol required follow up visits.&#xD;
&#xD;
          7. No significant pre-stroke disability (modified Rankin Score must be â¤ 2).&#xD;
&#xD;
          8. Females of childbearing potential must have a negative serum or urine pregnancy test.&#xD;
&#xD;
          9. Patient or patient's legally authorized representative has given Informed Consent&#xD;
             according to Good Clinical Practices (GCP) and/or local IRB policies.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Coma on admission (Glasgow Coma Scale &lt;8), need for intubation upon ED arrival, or&#xD;
             transferred patients who present previously intubated.&#xD;
&#xD;
          2. Severe agitation or seizures on admission that preclude safe vascular access.&#xD;
&#xD;
          3. Loss of airway protective reflexes and/or vomiting on admission.&#xD;
&#xD;
          4. Predicted or known difficult airway.&#xD;
&#xD;
          5. Pre-existing neurological or psychiatric disease that would confound the neurological&#xD;
             or functional evaluations, e.g. dementia.&#xD;
&#xD;
          6. Presumed septic embolus, or suspicion of bacterial endocarditis&#xD;
&#xD;
          7. Currently participating or has participated in any investigational drug or device&#xD;
             study within 30 days.&#xD;
&#xD;
          8. Inability to follow-up for 90-day assessment.&#xD;
&#xD;
          9. Known history of allergy to anesthesia drugs.&#xD;
&#xD;
         10. Known history or family history of malignant hyperthermia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peng Roc Chen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew Barreto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos Artime, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sunil Sheth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sean Savitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claudia Pedroza, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peng Roc Chen, MD</last_name>
    <phone>713-486-8016</phone>
    <email>peng.r.chen@uth.tmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eddie Aguilar, BA</last_name>
    <phone>713-486-7764</phone>
    <email>eddie.aguilar@uth.tmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Indiana University College of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bradley Bohnstedt, MD</last_name>
      <email>bbohnste@iu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lauren Snyder</last_name>
      <email>lmillar@iu.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Santiago Ortega-Gutierrez, MD, MSc</last_name>
      <email>santy-ortega@uiowa.edu</email>
    </contact>
    <contact_backup>
      <last_name>Heena Olalde, MSN</last_name>
      <email>heena-olalde@uiowa.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Santiago Ortega-Gutierrez, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>48150</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alex Abou-Chebl, MD</last_name>
      <email>AAbouC1@hfhs.org</email>
    </contact>
    <contact_backup>
      <last_name>Khalid Uddin</last_name>
      <email>kuddin1@hfhs.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Rochester Regional Health</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14617</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay Morrow, MD, PhD</last_name>
      <email>jay.morrow@rochesterregional.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kara Cristales, RN</last_name>
      <email>kara.cristales2@rochesterregional.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jay Morrow, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Health</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacey Q Wolfe, MD</last_name>
      <email>sqwolfe@wakehealth.edu</email>
    </contact>
    <contact_backup>
      <last_name>Wendy Jenkins, BSN</last_name>
      <email>wejenkin@wakehealth.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Stacey Wolfe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oklahoma University Health Science Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Geisinger Health</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clemens M Schirmer, MD, PhD</last_name>
      <email>cmschirmer@geisinger.edu</email>
    </contact>
    <contact_backup>
      <last_name>Chelsie Derr</last_name>
      <email>cmderr1@geisinger.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Clemens Schirmer, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Temple University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kadir Erkmen, MD</last_name>
      <email>Kadir.Erkmen@tuhs.temple.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kathleen Hatala, RN, BSN</last_name>
      <phone>215-707-4171</phone>
      <email>Kathleen.Hatala@tuhs.temple.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Memorial Hermann Hospital System - Memorial City Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sunil Sheth, MD</last_name>
      <phone>713-500-7897</phone>
      <email>sunil.a.sheth@uth.tmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Eddie Aguilar, BA</last_name>
      <email>eddie.aguilar@uth.tmc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel M Raper, MD</last_name>
      <email>Daniel.Raper@bcm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Wajeeha Abrar, MHA, MBBS</last_name>
      <email>Wajeeha.Abrar@bcm.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Daniel M Raper, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center Houston with Memorial Hermann Hospital System - The Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sunil Sheth, MD</last_name>
      <phone>713-500-7897</phone>
      <email>sunil.a.sheth@uth.tmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Eddie Aguilar, BA</last_name>
      <phone>713-486-7764</phone>
      <email>eddie.aguilar@uth.tmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Sunil A Sheth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Hermann Hospital System - The Woodlands Medical Center</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77380</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yazan Alderazi, MD</last_name>
      <email>Yazan.J.Alderazi@uth.tmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Eddie Aguilar, BA</last_name>
      <phone>713-486-7764</phone>
      <email>eddie.aguilar@uth.tmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Yazan Alderazi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 16, 2017</study_first_submitted>
  <study_first_submitted_qc>August 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2017</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Peng Roc Chen</investigator_full_name>
    <investigator_title>Professor in Neurosurgery</investigator_title>
  </responsible_party>
  <keyword>Acute stroke</keyword>
  <keyword>Cerebral Stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

